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Table1: Prevalence of radiographic OA of the knee, as a function of age and
gender
Gender, age
range
n
(knees)
Radiographic
osteoarthritis(%)
Grade 3 or4
changes(%)
Female 800 51.7* 19,4*
w49 84 10.7 0.0
50–59 82 22.0 1.2
60–69 218 43.6* 10.6*
70–79 302 67.9* 26.5*
80w 114 83.3* 47.4*
Male 626 31.3* 7.5*
w49 50 0.0 0.0
50–59 48 12.5 4.2
60–69 162 16.7* 3.7*
70–79 256 38,3* 9.0*
80w 110 59.1* 14.5*
*P < 0.001 for differences in prevalence between males and females for each par-
ticular age range, and in total.
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PREVALENCE OF KNEE OSTEOARTHRITIS AND IMPACT OF
HYALURONIC ACID TREATMENT ON PAIN AND MOBILITY IN A
CANADIAN REAL-WORLD POPULATION
R.J. Petrella y, D.P. Gill y, C. Wakeford z. yU Western Ontario, London, ON,
Canada; z Sanoﬁ Canada, Laval, QC, Canada
Purpose: Given the paucity of large, real-world datasets for the inves-
tigation of knee osteoarthritis, the purpose of this study was to identify
and describe the treatment patterns and effects of intra-articular hya-
luronic acid (HA) on knee osteoarthritis pain and mobility in a large,
Canadian, real-world population.
Methods: This is an observational, retrospective cohort of patients 18
years and older who, between June 1, 1999 and December 31, 2012 had:
1) a diagnosis of knee osteoarthritis identiﬁed by ICD9-10 and/or text
coding; 2) received at least 1 treatment cycle with intra-articular HA
and; 3) complete pain andmobility data [i.e., pain Visual Analogue Scale
(VAS) and 6-minute walk test measures] for each treatment cycle. Data
came from the Southwestern Ontario (SWO) database, which is a rep-
resentative primary care, researchable database of over 325,000 unique
patient records in Ontario, Canada. The SWO has compiled data con-
tinuously beginning from 1999 until present. This database has shown
similar prevalence to the Canadian population for several chronic dis-
eases and includes demographic, biometric, laboratory, diagnostic and
health resource measures as collected in a primary care setting. Treat-
ments were provided as per usual care of the provider. In addition to
demographic data, pain [VAS (0–10 cm) pre and post treatment at rest],
and mobility (6-minute walk test in meters) were examined in this
study. Differences within and between treatments were compared
using paired and independent samples t-tests.
Results: Among 325,000 patients in the SWO database, 20,187 patients
had a diagnosis of osteoarthritis of the knee (6.2% prevalence) with
6,618 receiving at least 1 treatment cycle of any intra-articular HA
product (33% prevalence). Treatments included Hylan G-F 20 (Synvisc,
Genzyme Biosurgery) (43%) and others (57%). Mean age (SD) was 57 (11)
years at diagnosis and 71 (18) years at the time of ﬁrst HA treatment. A
high proportion of patients were male (61%), overweight or obese
according to standard body mass index cut-points (>80%), had co-
morbidities [i.e., diabetes (10%); hypertension (66%); and dyslipidemia
(13%)], and were predominantly grade 2–3 on radiographic examina-
tion (>75%). On average, patients received between 3 and 8 HA treat-
ment cycles. Among all patients, VAS at rest (weight-bearing)
signiﬁcantly improved following treatment (7.2 cm to 4.1 cm, p < 0.05).
Mobility (6-minute walk test) also improved post-treatment (321 m to
423m, p< 0.05). Comparing Hylan G-F 20 with all other HA treatments,
post-treatment VAS at rest (weight-bearing) was signiﬁcantly lower
(3.3 cm vs 4.1 cm, p < 0.05) and distance walked (6-minute walk test)
was signiﬁcantly greater (463 m vs 399 m, p < 0.05).
Conclusions: Osteoarthritis of the knee is a signiﬁcant problem in
primary care affecting pain and mobility. In this Canadian real-worlddatabase, initial analyses indicated that treatment with intra-articular
HA may improve pain and mobility. This real-world database may be
used as a potential resource for further examination of the effectiveness
of HA for reducing pain and improving mobility in knee osteoarthritis.
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MULTIPLE SYMPTOMATIC JOINTS ARE ASSOCIATED WITH
INCREASED HEALTH RESOURCE UTILIZATION AMONG PATIENTS
UNDERGOING TOTAL KNEE ARTHROPLASTY FOR OSTEOARTHRITIS
M.G. Zywiel, R. Chaudhary, Y.R. Rampersaud, R. Gandhi,
N.N. Mahomed, A.V. Perruccio. Arthritis Program, University Health
Network; Univ. of Toronto, Toronto, ON, Canada
Purpose: Hospitals and surgeons continue to be under increased cost
pressure with respect to total knee arthroplasty (TKA), with increasing
material costs and decreasing reimbursements. Recent evidence sug-
gests that multiple symptomatic joint involvement in patients with
osteoarthritis (OA) may be associated with poorer patient reported
outcomes when compared to those who have a single symptomatic
joint. However, it remains unclear whether this is associated with any
differences in in-hospital resource utilization. The purpose of the
present study was to evaluate whether the presence of multiple
symptomatic joints is associated with differences in length of stay,
discharge disposition, American Society of Anesthesiologists (ASA)
class, post-operative adverse event rates, or episode of care costs from
the hospital perspective in patients undergoing primary TKA for OA.
Methods: All patients who underwent primary TKA for OA at a single
institution between April 2011 and October 2012 were reviewed.
Patients with a history of rheumatoid arthritis or inﬂammatory
arthropathy were excluded, as were patients undergoing bilateral
procedures. Prospectively collected demographic and clinical data,
including number and location of symptomatic joints, as well as ASA
class and discharge disposition were extracted. Data were liked with a
hospital administrative costing database. Post-operative adverse event
rates were tracked prospectively and included in the analysis. Patients
were grouped into three categories based on joint involvement: 1)
symptoms in the operated joint only, 2) symptoms in a total of 2–4
joints, and 3) ﬁve or more symptomatic joints. A total of 245 patients
were included, with 35, 99, and 111 in each group, respectively.
Results: Signiﬁcant differences were seen in mean length-of-stay
between patient groups (3.74, 3.96 and 4.19 days respectively; p ¼
0.042), with longer time to discharge in patients with multiple joint
involvement. These differences were maintained when patients dis-
charged to rehabilitation facilities were excluded (p ¼ 0.015), and were
not explained by differences in mean patient age (64, 65 and 65 years of
age respectively; p ¼ 0.925), the need for stair training before discharge
home (93%, 93% and 86% of patients; p ¼ 0.290), or in-hospital adverse
event rates (p ¼ 0.315). No signiﬁcant differences in the proportion of
patients discharged to home were identiﬁed based on degree of multi-
joint involvement (83%, 81% and 76% respectively; p ¼ 0.540). Multiple
joint involvement was positively associated with increasing mean ASA
class (2.26, 2.33, 2.61 respectively; p < 0.001), but was not correlated
with the incidence of in-hospital adverse events (r ¼ 0.012). Increasing
joint involvement was associated with signiﬁcantly greater mean epi-
sode of care costs from a hospital perspective (p ¼ 0.024), and this
relationship was maintained when the analysis was limited to patients
who were discharged home (p ¼ 0.011). Patients with involvement of 5
or more joints accrued an incremental 9% cost burden to the hospital
when compared to those with single joint disease ($10,251 vs $9,379
per patient). Assuming a similar nation-wide prevalence of multiple
joint symptoms, this represents a total incremental cost burden of
$19,500,000 per year to the Canadian health care system based on
2008/2009 nationwide case volumes.
Conclusions: The results of the present study provide evidence of dif-
ferences in in-hospital health resource utilization following TKA for OA
between patients who have multiple symptomatic joints when com-
pared to those with a minimal number of symptomatic joints. These
patients appear to have a greater severity of systemic disease as evi-
denced by greater mean ASA scores, although this did not translate into
Abstracts / Osteoarthritis and Cartilage 22 (2014) S57–S489 S223an increased risk of post-operative in-hospital adverse events. While no
signiﬁcant differences were seen in discharge disposition, patients with
multiple symptomatic joints spent an average of half a day longer in
hospital before discharge when compared to those with symptoms in
the operated joint only, and accrued almost 10% greater costs from the
hospital perspective. Physicians and other health care decision makers
should be aware that multi-joint OA may characterize a distinct clinical
entity that may warrant speciﬁc attention.
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MULTIPLE SYMPTOMATIC JOINTS ARE ASSOCIATED WITH
INCREASED IN-HOSPITAL RESOURCE UTILIZATION AMONG
PATIENTS UNDERGOING TOTAL HIP ARTHROPLASTY FOR
OSTEOARTHRITIS
M.G. Zywiel, L.D. Djelic, R. Chaudhary, Y.R. Rampersaud, R. Gandhi,
N.N. Mahomed, A.V. Perruccio. Arthritis Program, University Health
Network; Univ. of Toronto, Toronto, ON, Canada
Purpose: The presence of multiple symptomatic joints has been asso-
ciated with worse pre-operative knee-speciﬁc pain and function in
patients undergoing total knee arthroplasty for osteoarthritis (OA).
However, it remains unknown whether similar patterns are seen in
patients with end-stage hip OA. The purpose of the present study was to
evaluate whether the presence of multiple symptomatic joints is
associated with differences in pre-operative hip-speciﬁc pain and
function, American Society of Anesthesiologists (ASA)class, adverse
event rates, length of stay, discharge disposition, or episode of care costs
in patients undergoing primary total hip arthroplasty (THA) for OA.
Methods: All patients who underwent primary THA for OA at a single
institution between April 2011 and October 2012 were reviewed.
Patients with a history of rheumatoid arthritis or inﬂammatory
arthropathy were excluded. Prospectively collected demographic and
clinical data, including number and location of symptomatic joints, as
well as ASA class and discharge disposition were extracted and linked
with hospital administrative data. Patients were grouped into three
categories: 1) symptoms in the operated joint only, 2) symptoms in a
total of 2–4 joints, and 3) ﬁve or more symptomatic joints. A total of 203
patients were included, with 46, 96, and 61 in each group, respectively.
Differences in hospital costs and length of stay were extrapolated to
determine the potential nationwide health services impact of multi-
joint osteoarthritis in Canada and the United States.
Results: Increasing symptomatic joint count was associated with sig-
niﬁcantly worse hip-speciﬁc mean WOMAC pain (8.59, 9.3, and 10.5
points respectively; p ¼ 0.018) and function (29.9, 32.2 and 37.2 points
respectively; p ¼ 0.010) scores, as well as greater mean ASA class (p ¼
0.001). The difference in mean length of stay between single joint and
5þ symptomatic joints groups was 0.17 days (one additional in-hospital
day for every 6 patients), irrespective of whether all patients or only
those patients discharged home were considered. No differences in the
incidence of adverse events were seen. However, the presence of ﬁve or
more symptomatic joints was associated with signiﬁcantly greater in-
hospital episode of care costs (10% incremental difference compared to
the single joint group; p ¼ 0.029), irrespective of discharge disposition.
Assuming the 30% prevalence of multiple symptomatic joints observed
in the present sample is representative of the nationwide population of
patients undergoing THA, this is conservatively estimated to represent
an incremental burden from the hospital perspective of $8,296,000
(CAD) when compared to procedures performed in patients with a
single symptomatic joint, and an additional 1,543 in-hospital bed-days.
When extrapolated to case volumes in the United States, this represents
an incremental cost burden of $67,356,000 (USD) and an additional
12,903 hospital bed-days to the US healthcare system in 2010, poten-
tially rising to $152,283,000 unadjusted USD and an additional 29,172
hospital bed-days by 2030.
Conclusions: Given the large and increasing number of patients
undergoing THA, the presence of multiple symptomatic joints may have
substantial health services implications as a result of higher incre-
mental hospital costs and increased length of stay. Further study is
needed to better characterise the differences in in-hospital health
resource requirements to identify the speciﬁc reasons for these dis-
parities. However, physicians and other health care decision makersshould be aware that OA associated with multiple symptomatic joints
may characterize a distinct clinical entity, potentially warranting spe-
ciﬁc attention and intervention.
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ARTHRITIS AND BACK PAIN IMPACT RESPIRATORY-SPECIFIC
QUALITY OF LIFE MEASURES IN SMOKERS WITH AND WITHOUT
COPD
E.A. Regan y, G.L. Kinney z, J. Black-Shinn z, M-L. McDonald x,
F. Jacobson x, B. Make y, J. Hokanson z, E. Silverman x, J.D. Crapo y. yNatl.
Jewish Hlth., Denver, CO, USA; zUniv. of Colorado Denver, Denver, CO, USA;
xBrigham and Women’s Hosp. and Harvard Med. Sch., Boston, MA, USA
Purpose: COPD affects more than 10 million people in the US and
approximately 49% of the US population over age 45 is a current or ex-
smoker. Comorbid arthritis and degenerative spine disease occur in
aging smokers but the prevalence of these conditions in smokers and
their impact on respiratory-speciﬁc quality of life measures has not
been studied. We hypothesized that either condition might impact the
St George Respiratory Questionnaire (SGRQ) – which is the most com-
monly used instrument in both COPD clinical trials and the assessment
of COPD progression. We have previously found strong associations of
osteoporosis to smoking and COPD severity.
Methods: COPDGene is a longitudinal cohort of 10,192 current and ex-
smokers, age 45 -80, designed to assess subtypes of COPD and their
genetic associations. Baseline cross-sectional data from the smoker
controls and from COPD subjects was used. Study data included self-
reports of musculoskeletal diseases and physical complaints. We
identiﬁed those with osteoarthritis (OA) based on self-report of
physician-diagnosis. Chronic back pain was identiﬁed by a positive
response to “Do you have lower back, buttock, or radiating leg pain
most days of the month?” We determined the prevalence of OA and
Chronic Back Pain (CBP) by age groups and by severity of lung disease.
Using multivariable regression adjusting for age, gender, obesity and
race, we tested the association of current smoking and pack years to
OA and chronic back pain. We compared these results to similar
analyses of self-reported osteoporosis, osteoporosis based on volu-
metric QCT measures, and rheumatoid arthritis based on self-report
and disease-modifying anti-rheumatic drugs (DMARD) use. Multi-
variable regression (adjusting for age, gender, race, smoking status and
pack years) was used to assess the impact of each of these conditions
on SGRQ scores and on the SF-36.
Results: Self-reported OA is slightly more prevalent in COPD cases (21%)
than controls (17%) in univariate analysis but the association is not
present after adjustment for age, gender, and race (OR 0.9, 95% CI 0.8–
1.0, p ¼ 0.07). There are expected associations to female gender, obesity
and increased age in univariate and multivariable analyses. In this
smoker cohort, the overall prevalence of OA is 19% but increases by age
group up to 40% in the 60–70 year old age group. Neither current
smoking nor pack years were associated with OA in multivariable
models. Chronic back pain is also not associated with COPD, but is
strongly associated with African American race, female gender, obesity,
current smoking and pack years in multivariable models. Both OA and
back pain have signiﬁcant negative effects on respiratory health status
exceeding the minimal clinically signiﬁcant difference of 4 units in
COPD patients), but the magnitude of the effect from chronic back pain
is three-fold greater than OA (range 11 -20 units). The generic quality of
life instrument, SF-36 showed similar results with both conditions
demonstrating signiﬁcant impairment, but chronic back pain had a 3 to
5-fold greater effects on physical function, bodily pain and physical
component scores.
Conclusions: Osteoarthritis and chronic back pain are common in a
smoking cohort and in COPD patients, but show divergent associations
with smoking. Chronic back pain has much greater impact on quality of
life than osteoarthritis of the lower extremities. Both conditions affect
quality of life measurements using a respiratory-speciﬁc instrument.
Clinical trials that use the SGRQ to measure outcomes of treatment in
COPD should assess subjects for OA and chronic spine disease to avoid
confounding. Drug treatments for COPD that are directed toward con-
trolling inﬂammation may improve respiratory-speciﬁc quality of life
scores as a result of improved musculoskeletal function.
